FDA Approves Opdivo for First-Line Hodgkin Lymphoma Treatment

Bristol Myers Squibb's Opdivo has received FDA approval for the treatment of Hodgkin lymphoma as a first-line combination regimen. The FDA has expanded Opdivo's label to include this indication, marking a significant milestone for the company. Opdivo is an antitumor therapy that has shown promise in treating various types of cancer.